These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17373754)

  • 1. A prophylactic approach for bone marrow transplantation from a hepatitis B surface antigen-positive donor.
    Sobhonslidsuk A; Ungkanont A
    World J Gastroenterol; 2007 Feb; 13(7):1138-40. PubMed ID: 17373754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B immunoglobulin in combination with lamivudine for prevention of hepatitis B virus reactivation in children undergoing bone marrow transplantation.
    Tavil B; Kuşkonmaz B; Kasem M; Demir H; Cetin M; Uçkan D
    Pediatr Transplant; 2006 Dec; 10(8):966-9. PubMed ID: 17096768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation.
    Hashino S; Nozawa A; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Suzuki S; Hige S; Asaka M
    Bone Marrow Transplant; 2002 Feb; 29(4):361-3. PubMed ID: 11896435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
    Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.
    Imamura T; Yokosuka O; Chiba T; Kanda T; Kojima H; Fukai K; Imazeki F; Nishimura M; Saito Y; Saisho H
    Leuk Lymphoma; 2005 Jun; 46(6):915-7. PubMed ID: 16019538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients.
    Ilan Y; Nagler A; Zeira E; Adler R; Slavin S; Shouval D
    Bone Marrow Transplant; 2000 Sep; 26(6):633-8. PubMed ID: 11035369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation.
    Suehiro T; Shimada M; Kishikawa K; Shimura T; Soejima Y; Yoshizumi T; Hashimoto K; Mochida Y; Maehara Y; Kuwano H
    Liver Int; 2005 Dec; 25(6):1169-74. PubMed ID: 16343068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful allogeneic bone marrow transplantation from an HBV-positive donor into an HBV-positive recipient using lamivudine.
    Hashino S; Takahata M; Nozawa A; Izumiyama K; Chiba K; Suzuki S; Hige S; Asaka M
    Bone Marrow Transplant; 2002 Feb; 29(3):269-71. PubMed ID: 11859401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B-positive donors in renal transplantation: increasing the deceased donor pool.
    Pilmore HL; Gane EJ
    Transplantation; 2012 Aug; 94(3):205-10. PubMed ID: 22430067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG; Suyanı E; Özenirler S; Sucak GT
    Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature.
    Loggi E; Conti F; Cucchetti A; Ercolani G; Pinna AD; Andreone P
    World J Gastroenterol; 2016 Sep; 22(35):8010-6. PubMed ID: 27672295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation.
    Yu S; Yu J; Zhang W; Cheng L; Ye Y; Geng L; Yu Z; Yan S; Wu L; Wang W; Zheng S
    J Hepatol; 2014 Oct; 61(4):809-15. PubMed ID: 24824283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.